Enhancement of Tumor Outgrowth Through CTL Tolerization After Peptide Vaccination Is Avoided by Peptide Presentation on Dendritic Cells
René E. M. Toes(Leiden University Medical Center), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Jan W. Drijfhout(Leiden University), Louis van Bloois(Utrecht University), W. Martin Kast(University of Southern California), Gert Storm(Yong In University), Rienk Offringa(German Cancer Research Center), Ellen I. H. van der Voort(Leiden University), Stephen P. Schoenberger(La Jolla Institute for Immunology)
Cited by 147
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization
|Frontiers in Pharmacology|2018|937
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851